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1. Introduction 
Orthotopic liver transplantation (OLT) was initially developed in the 1960s as treatment for 
individuals dying of end-stage liver disease. It began to be utilized in the 1980s as salvage 
therapy in the setting of acute liver failure (ALF). Prior to the use of OLT, ALF mortality 
rates reached 80-85%, and the early post-transplant survival rates were much lower than 
those following transplantation for chronic liver diseases (Bernuau et al., 1986a). Over the 
past thirty years, however, with advances in critical care management and in the field of 
liver transplantation, 1-year survival rates following OLT for ALF have improved to 60-80% 
(Bismuth et al., 1995; DeVictor et al., 1992; Hoofnagle et al., 1995; W Lee, 2003; O'Grady et 
al., 1988). ALF is one of the few conditions for which a patient can be listed as a United 
Network for Organ Sharing (UNOS) status 1A (urgent) patient in the United States and 
“super urgent” in the United Kingdom. Although about half of ALF patients undergo OLT, 
ALF accounts for less than 10% of US transplants and approximately 11% in Europe 
(Freeman et al., 2008). 
2. Prognosis and prognostic models 
It is essential to quickly and accurately identify those patients most likely to benefit from 
emergent OLT. In the setting of organ shortage, it is also important to identify and even 
delist patients who are too ill to benefit from OLT. To minimize the risk of unnecessarily 
committing individuals to lifelong immunosuppression, one must balance the desire to 
delay transplantation to allow for the potential of spontaneous recovery against the risk of 
death with that delay and the risk of the surgery itself. Many ALF patients who have been 
listed for OLT will recover spontaneously without transplantation and it is estimated that 
as many as 20% of patients may be transplanted needlessly. In addition, a significant 
number of ALF patients listed for OLT will die awaiting a donor organ. In the United 
Kingdom, about 30% of patients initially considered for OLT ultimately become 
untransplantable following the development of complications (i.e., cerebral edema, sepsis, 
hemodynamic abnormalities, multiorgan system failure) (Bernal et al., 1998). Additionally, 
many patients have medical or psychosocial contraindications to transplantation, including 
irreversible brain injury, underlying cardiovascular disease, infection/sepsis, alcohol or 
drug abuse, poorly controlled psychiatric disease, or inadequate family support (Simpson 
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et al., 2009). Thus, it is important to identify and delist patients who are too ill to benefit 
from OLT. 
It is crucial that reliable predictive models of survival and the need for OLT be developed. 
Successfully predicting outcome would allow more judicious use of scarce organs and spare 
those who will ultimately recover the need for lifelong immunosuppression. There are at 
present no standardized criteria to predict who should be listed for OLT. Several prognostic 
models have been developed to help identify appropriate patients for transplantation. 
Unfortunately, these prognostic models have limitations, and their predictive accuracy 
varies (Blei, 2005; Anand et al., 1997).  
2.1 Predictors of prognosis 
Many factors may help determine which ALF patients are more likely to die; however, they 
are generally unreliable in predicting who will ultimately survive or require transplantation.  
2.1.1 Etiology 
The etiology of ALF is one of the most important predictors of spontaneous outcome 
(Ostapowicz et al., 2002). The lowest mortality is seen with ALF secondary to 
acetaminophen (N-acetyl-p-aminophenol; APAP) toxicity (~30%), hepatitis A virus infection 
(~50%), shock liver, and pregnancy-related ALF (Larson et al., 2005; Ostapowicz et al., 2002; 
Schiodt et al., 2003). In contrast, the non-transplant mortality for the remainder of causes, 
including ALF secondary to drug-induced liver injury, remains abysmal (80% to 100%) 
(O'Grady et al., 1988; Ostapowicz et al., 2002). Therefore, understanding which causes of 
ALF predominate in a particular region can help lead to the early evaluation and listing of 
these latter cases for OLT. 
ALF secondary to drug-induced liver injury (DILI) predominates in Europe and North 
America, with a high prevalence of APAP-induced ALF in the US and United Kingdom 
(Hoofnagle et al., 1995; Larson et al., 2005; Ostapowicz et al., 2002; Schiodt et al., 1999; 
Williams, 1996). Viral hepatitis predominates in developing countries. The US ALF study 
group looked at 1198 patients with ALF over an 11 year period and a total of 133 (11.1%) 
subjects were deemed by expert opinion to have DILI ALF. Transplant-free (3-week) 
survival was poor (27.1%), but with successful transplantation in 42.1%, overall survival was 
66.2%. Transplant-free survival in DILI ALF is determined by the degree of liver 
dysfunction, specifically baseline levels of bilirubin, prothrombin time/international 
normalized ratio (PT/INR), and Model for End-Stage Liver Disease (MELD) scores (Reuben 
et al., 2010).  
In the United Kingdom, the number of patients with APAP ALF has declined due to 
legislative changes in drug packaging, leading to an increase in the relative number of 
cryptogenic or seronegative cases (16% of all ALF). The majority (88%) of these latter ALF 
patients met King’s College transplant criteria (see below), reflecting the low likelihood of 
spontaneous recovery (Wigg et al., 2005). A recent study from the UK suggested that OLT is 
a more favorable approach to managing patients with non-APAP induced ALF compared to 
patients with APAP induced ALF. This was predominantly due to the frequent psychosocial 
contraindications in patients with APAP induced ALF (Simpson et al., 2009).  
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2.1.2 Clinical and laboratory criteria 
The clinical criteria most commonly used to exclude a patient from OLT vary by transplant 
center but may include age older than 70 years, the presence of certain malignancies outside 
of the liver, severe cardiac, lung, or multiple organ failure, severe infection, uncontrolled 
septic shock and brain death (Table 1) (Samuel & Bismuth, 2001). Patients with grade 3-4 
encephalopathy and fixed pupils, cerebral perfusion pressure <40 mmHg, sustained 
elevation in intracranial pressure >50 mmHg, or seizures are at high risk for postoperative 
neurologic complications or brain death. They are usually not deemed candidates for OLT 
(Bismuth et al., 1995). As long as the pupils remain active and the patient does not have 
posturing movements, liver transplantation can still be considered (Daas et al., 1995). The 
degree of serum aminotransferase elevation and the rate of its recovery do not predict 
prognosis. In fact, improvement of aminotransferase levels in conjunction with worsening 
bilirubin, hepatic encephalopathy, and coagulopathy (INR) signals complete liver failure 
and is a particularly ominous sign.  
Common Exclusion Criteria 
Age >70 years old (relative) 
Certain malignancies outside of the liver 
Severe cardiac, lung, or multiple organ failure 
Severe infection 
Uncontrolled septic shock 
Brain death 
UNOS Status 1a Listing Criteria for ALF 
Age ≥ 18 years 
Life expectancy without a liver transplant of <7 days 
Onset of encephalopathy within 8 weeks of the first symptoms of liver disease 
Absence of pre-existing liver disease (except for the diagnosis of fulminant Wilson’s 
disease) 
Residence in the intensive care unit 
At least one of the following: ventilator dependence, renal replacement therapy, or INR 
>2.0 
Table 1. Exclusion and Listing Criteria for Transplantation for Acute Liver Failure. INR-
international normalized ratio 
2.1.3 Multiorgan failure 
The severity of multiorgan failure at the time of OLT is also a predictor of post-transplant 
survival. Decreased renal function is associated with worse spontaneous survival in non-
APAP-induced liver injury. In a multivariate analysis of UNOS data (1988–2003), four risk 
factors predicting post-transplant survival were identified: pretransplant use of life support, 
recipient age >50 years, recipient body mass index ≥30 kg/m2, and serum creatinine 
>2 mg/dL. If an individual had all of these risk factors, the 5-year post-transplant survival 
was only 44–47%. Whereas, if none of these features were present, the 5-year post-transplant 
survival was 82–83% (Barshes et al., 2006).  
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2.1.4 Hepatic encephalopathy 
Mortality rates correlate with the severity of hepatic encephalopathy (HE), reported at 30% 
for grade 2, 45-50% for grade 3 and 80-90% for grade 4 HE (Daas et al., 1995; Hoofnagle et 
al., 1995). A multicenter US series, in which 39% participants had APAP hepatotoxicity, 
showed a 52% 3-week transplant-free survival in patients with grade 1-2 encephalopathy, 
but only 33% with grade 3-4 HE survived without transplant (Ostopowicz et al., 2002). 
Conversely, 85% of patients with non-APAP ALF without HE experienced spontaneous 
recovery (Elinav et al., 2005). Paradoxically, those with more rapid development of HE (i.e., 
APAP-induced) appear to have a better outcome than those with a longer interval between 
the development of symptoms and HE (i.e., DILI) (Bernuau et al., 1986a; O'Grady et al., 
1989; O'Grady et al., 1993). A distinctive feature ALF-induced HE is the development of 
cerebral edema, the complete pathophysiology of which remains poorly understood. 
Cerebral edema develops in nearly 80% of patients who progress to grade 4 HE, leading to 
intracranial hypertension with subsequent ischemic brain damage or brainstem herniation, 
accounting for up to 50% of ALF mortality (Clemmensen et al., 1999; Jalan et al., 2003). 
Intracranial pressure (ICP) monitoring is more often utilized in patients who are deemed 
candidates for OLT, and ICP may be more aggressively managed in these cases. ICP 
monitors may also be of significant value during the transplant operation, when fluctuations 
in ICP are common (Philips et al., 1998). ICP monitoring is associated with up to a 10% risk 
of intracranial hemorrhage, and it has not been shown to change 30 day post-OLT survival 
(Gasco et al., 2010). Thus, the indication and timing of use of ICP monitoring devices remain 
controversial (Vaquero et al., 2005). Intracranial hypertension may persist during the first 
10-12 hours following liver transplantation, thus ICP monitoring, if utilized, should 
continue during and after surgery (Bismuth et al., 1995; Jalan et al., 2003).  
2.1.5 Infection 
ALF-induced hemodynamic changes can be difficult to distinguish from infection and sepsis 
and are complicated by the fact that ALF patients may not develop leukocytosis or fever. 
Bacterial infection is the cause of death in up to 37%, with the most common sites of 
infection being pulmonary (47%), blood (26%), and urine (23%) (Bernal et al., 2003). Fungal 
infections, especially Candida sp., are seen in up to 32%, occur later in the course of disease, 
particularly after use of antibiotics or in the setting of renal dysfunction, and are often 
associated with bacterial infection (Rolando et al., 1991; Vaquero et al., 2003). Active 
infection is a contraindication to OLT. The empiric use of antibiotics is controversial. 
Prophylactic antibiotics decrease the number of infections, but do not change overall 
outcome (Rolando et al., 1990; Rolando et al., 1996; Stravitz et al., 2007). Some centers 
administer anti-infectives (antibacterial and antifungal) to patients who have significant 
isolates on surveillance cultures, have progression to Stage 3-4 HE, have refractory 
hypotension, or have clinical evidence of systemic inflammatory response syndrome 
(Stravitz et al., 2007). Periodic surveillance cultures and frequent chest radiographs can help 
detect bacterial and fungal infections early. 
2.1.6 Psychosocial predictors 
The burden of medical follow-up after OLT can be substantial, and quality of life can be 
significantly affected. Therefore, the decision to offer OLT to an individual patient also 
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needs to consider more controversial issues such as psychosocial factors (i.e., adequacy of 
social support and substance and/or alcohol abuse), and adequacy of medical insurance 
coverage. For example, in one study, four patients (12%) died in the post-transplant follow-
up period from deliberate self-harm (Bernal et al., 1998).  
2.2 Prognostic models 
Multiple prognostic models have been proposed to help determine the likelihood of 
spontaneous survival (Table 2) (Antoniades et al., 2007; Bailey et al., 2003; Bernuau et al., 
1986b; Bernuau, 1993; Craig et al., 2010; Harrison et al., 1990; Itai et al., 1997; O'Grady et al., 
1989; Pereira et al., 1992; Rolando et al., 2000; Schiodt et al., 2005; Van Thiel, 1993). However, 
many of these models are methodologically flawed and subject to bias. In addition, many 
equate OLT with death, which falsely elevates the positive predictive value of these 
prognostic systems (Craig et al., 2010).  
Variable Clichy King’s 
Criteria 
APAP 
King’s 
Criteria  
non-APAP 
APACHE 
II 
MELD 
Factor V Level X     
Age X  X X  
Hepatic 
Encephalopathy 
X X  X  
Arterial pH  X  X  
INR  X X  X 
Serum Creatinine  X  X X 
Etiology   X   
Serum Bilirubin   X  X 
Duration of 
Jaundice 
  X   
Vital Signs  
(T, BP, HR, RR) 
   X  
Oxygenation    X  
Serum Na & K    X  
WBC    X  
Hematocrit    X  
Table 2. Comparison Between the Various Prognostic Scoring Systems for Acute Liver 
Failure APAP-acetaminophen; MELD-model for end-stage liver disease; INR-international 
normalized ratio; T-temperature; BP-blood pressure; HR-heart rate; RR-respiratory rate;  
Na-sodium, K-potassium; WBC-white blood cell count. Clichy (Bernuau et al, 1986); King's 
Criteria (Bernal et al., 2002; O'Grady et al., 1989), Apache II (Mitchell et al., 1998); MELD 
(Schmidt & Larsen, 2007; Villamil et al., 2007; Wiesner, 2004; Yantorno et al., 2004; Zaman et 
al., 2006) 
2.2.1 King's college hospital criteria 
The most widely applied prognostic system are the King’s College Hospital criteria (King’s 
criteria) developed from a retrospective cohort of nearly 600 patients (Bernal et al., 2002; 
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O'Grady et al., 1989). The Kings criteria incorporate both the etiology of ALF (APAP- versus 
non-APAP induced ALF) and clinical parameters of disease (O'Grady et al., 1989). In a meta-
analysis of studies using the Kings criteria, the pooled sensitivity and specificity was 69% 
and 92%, respectively (Bailey et al., 2003). The Kings criteria appear to have high positive 
predictive values (80% in APAP induced ALF and 70-90% in non-APAP induced ALF) but 
poorer negative predictive values (70-90% and 25-50%, respectively). A recent meta-analysis 
found that the Kings criteria for non-APAP induced ALF have good specificity, especially 
for patients with high grade encephalopathy (McPhail et al., 2005). The Kings criteria are 
helpful in identifying those who may need OLT, but up to 20% of those meeting criteria 
potentially could have survived without OLT, and those not meeting criteria may still 
require transplantation. The addition of arterial blood lactate levels to the model has 
improved its sensitivity (Bernal et al., 2002; MacQuillan et al. 2005).  
2.2.2 Other models and predictors 
Other Models and Predictors. The Clichy criteria were developed in a cohort of French 
patients with acute hepatitis B virus infection (Bernuau et al., 1986b). These criteria suggest 
that a serum factor V level of <20% in patients younger than 30 years or <30% in any patient 
with grade 3-4 HE has validity as a marker of mortality. The criteria predicted a poor 
outcome with a sensitivity and specificity of 86% and 76%, respectively. Factor V level 
measurements are less readily available to the clinician than are the measures in the Kings 
criteria, therefore, this prognostic model is not commonly utilized (Izumi et al., 1996; 
Pauwels et al., 1993). In addition, this model has not been validated in the non-HBV 
population. A factor V <10% has been shown to predict a poor outcome with a sensitivity of 
91% and a specificity of 100%; while a factor VIII : V ratio of >30 similarly predicts outcome 
(91% sensitivity, 91% specificity) (Pereira et al., 1992). The admission Acute Physiology and 
Chronic Health Evaluation (APACHE) II is ineffective in predicting who will survive 
without transplantation, since many patients who do not meet the severity criteria will 
ultimately die of subsequent complications (Mitchell et al., 1998).  
Elevated arterial ammonia levels increase the risk of developing intracranial hypertension. 
A level of >150 µmol/L predicts development of intracranial hypertension with a sensitivity 
of 60% and a specificity of 84% (Kitzberger et al., 2009). Concentrations of more than 100-
150 µmol/L have been positively correlated with cerebral herniation (Bernal et al., 2007; 
Bhatia et al., 2006; Clemmensen et al., 1999; Toftent et al., 2006).  
Serum alpha-fetoprotein (AFP) is generally considered a marker of hepatocellular 
regeneration. There has been no consistent correlation seen between the absolute AFP level 
and outcome in ALF (Tofteng et al., 2006). However, an increasing AFP level has been 
strongly associated with a more favorable outcome (Schiodt et al., 2006; Yang et al., 2002).  
A threshold AFP of ≤3.9 μg/L at 24 hours following the peak ALT identified nonsurvivors 
with a sensitivity and specificity of 100% and 74%, respectively, and a negative predictive 
value of 100% (Schmidt et al., 2005). In addition, it has been shown that a rising AFP level 
between day 1 and day 3 from presentation predicted survival without transplantation, 
whereas a decreasing level was seen in 80% of those who died (Schiodt et al., 2006).  
Persistently elevated phosphate levels may be associated with a poorer prognosis in the 
setting of acetaminophen-induced ALF. A serum phosphate level >1.2 mmol/L on day 2 or 
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3 following APAP overdose carries a sensitivity of 89% and a specificity of 100% for 
predicting poor outcome (Baquerizo et al., 2003; Chung et al., 2003; Schmidt et al., 2003). The 
level of Gc-globulin, a protein which is markedly reduced in the setting of tissue injury, has 
not been shown to reliably predict survival in those with APAP-induced ALF. In non-APAP 
ALF; however, using a cutoff value of ≤80 mg/L, the Gc-globulin level carries a positive 
predictive value of 74% and a negative predictive value of 81% (Schiodt et al., 2005; Schiodt 
et al., 2007)). An elevated arterial blood lactate level following volume resuscitation predicts 
worse survival in APAP-induced ALF (Bernal et al., 2002; Cholongitas et al., 2008; 
MacQuillan et al. 2005).  
The model for end-stage liver disease (MELD) scoring system, is an excellent prognostic 
model for chronic liver disease (Schmidt & Larsen, 2007; Villamil et al., 2007; Wiesner, 2004; 
Yantorno et al., 2004; Zaman et al., 2006). However, it has been limited as a prognostic 
model in ALF, because it does not account for most of the extremely important outcome 
predictors in ALF, including age, etiology of ALF and duration of jaundice. The MELD score 
has a sensitivity and specificity of <75% for predicting outcome in all forms of ALF (Bernal 
et al., 2007; Dhiman et al., 2007; Riorden & Williams, 2003). Whether modification of the 
MELD with these important factors would improve the MELD as standard scoring system 
in prognosis of ALF remains to be seen. Dhiman and colleagues compared clinical 
predictors of MELD and Kings criteria in patients with ALF. Clinical predictors were 
superior to both MELD and Kings criteria in predicting prognosis of ALF. Significant factors 
included age >50 years, jaundice to encephalopathy time greater than 7 days, grade 3-4 
encephalopathy, cerebral edema, prothrombin time ≥35 seconds, and serum creatinine 
≥1.5mg/dL) are associated with a poor prognosis. The presence of 3 or more of these factors 
is associated with a poorer prognosis (Dhiman et al., 2007; O'Grady et al., 2007). Molecular 
markers of cell apoptosis have also been found to be helpful prognostic factors. Bechmann 
looked at replacing the bilirubin value in the MELD score with the ratio of CK18/M65, a 
marker of cell death. This model was found to be associated with higher sensitivity and 
specificity. Although this study was limited by a small number of patients, the idea of using 
molecular markers of cell death in predicting prognosis of ALF is promising and needs to be 
studied in larger cohorts (Bechmann et al., 2010). Cytokeratin 18-based modification of the 
MELD score improves prediction of spontaneous survival after acute liver injury. 
In effort to develop a functional scoring model for non-APAP induced ALF, Miyaki and 
colleagues looked at 4 prognostic factors – etiology of ALF, hepatic coma grade (III or IV), 
systemic inflammatory response syndrome, and ratio of total to direct bilirubin (>2.0). The 
authors found these factors to be predictors of 2-week outcome with high positive and 
negative predictive values, 93.3%, and 81.8%, respectively (Miyake et al., 2005). This 
prognostic model would help the clinician predict prognosis and consideration for liver 
transplantation for patients with non-APAP ALF, however it requires validation before it 
can be widely clinically applied.  
A liver volume of <1000 mL on computed tomography (CT) imaging is also associated with 
a high mortality rate, a finding which has been validated (Shakil et al., 2000; Yamagishi et 
al., 2009). Based upon these findings, a prognostic formula has been proposed, but is not 
widely utilized. Liver biopsy may also be helpful in determining the cause of the ALF and, 
theoretically, the severity and extent of liver damage. Hepatic necrosis of more than 70% 
was associated with a transplant free survival of <10% in one analysis (Scotto et al., 1973). 
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However, there is a great degree of sampling error, and more recently, a multivariate 
analysis of 97 consecutive patients found that the amount of necrosis was not predictive of 
mortality (Miraglia et al., 2006; Voigt et al., 2007).  
Based upon the available data, the current prognostic scoring systems have not consistently 
demonstrated reliable accuracy in predicting outcome from ALF and the subsequent need 
for OLT. Therefore, the American Association for the Study of Liver Diseases (AASLD) does 
not recommend reliance on any one of these systems (W Lee & Larson, 2005).  
3. Liver transplantation 
As previously noted, advances in critical care management of ALF patients has improved 
the spontaneous survival from 10-20% to about 40% without transplantation (Ostapowicz et 
al., 2002). For those who will not spontaneously recover; however, OLT remains the only 
treatment modality that improves survival. With the advent of use of OLT in this setting, 
overall survival rates have further improved to about 60%. 
3.1 Transplant listing criteria 
Candidacy for liver transplantation must be determined quickly in the setting of ALF, given 
the rapid progression of the syndrome. In the US, ALF is one of the few conditions for 
which a patient can be listed as a United Network for Organ Sharing (UNOS) status 1A 
(urgent) patient (available at http://www.unos.org) (Table 1). ALF patients may be listed in 
the “super urgent” category in the United Kingdom. Approximately half of ALF patients 
undergo liver transplantation; however, ALF accounts for less than 10% of US transplant 
and 11% in Europe (Freeman et al., 2008; Organ Procurement & Transplantation Network 
[OPTN], 2009).  
3.2 Types of liver transplantation 
In addition to whole-organ deceased donor liver transplantation (DDLT), which is 
preferred, various types of liver transplantation may be considered depending on the 
situation: living donor liver transplants, ABO-compatible transplants, ABO-incompatible 
transplants and auxiliary liver transplants. In the setting of organ shortage, the risk of 
mortality awaiting an organ should be weighed against the risk of complications or failure 
using an alternative graft (Table 3). 
 
OLT LDLT 
ABO-
compatible 
ABO-
incompatible 
Heterotopic 
auxiliary LT 
Auxiliary partial 
LT 
Graft 75 56-90 49-54 39-52   
Patient 82 59-90  30 33 71 
Table 3. One-Year Post-Transplant Sruvival Rates for Acute Liver Failure (percent). OLT-
orthotopic liver transplantation; LDLT-living donor liver transplantation, LT-liver 
transplantation. OLT (O'Mahony et al., 2007); LDLT (Ichida et al., 2000; S Lee et al., 2007; 
Miwa et al., 1999; Uemoto et al., 2000); ABO-Compatible (Bismuth et al., 1996b); ABO-
incompatible (Bismuth et al., 1996b; Farges et al., 1995); Heterotopic (Van Hoek et al., 1999); 
Auxillary Partial (Van Hoek et al., 1999) 
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3.2.1 Living donor liver transplantation (LDLT) 
The use of LDLT in this setting remains controversial (Campsen et al., 2008; Liu et al., 2002; 
Nishizaki et al., 2002; Uemoto et al., 2000). It is imperative to consider the need for an 
adequately sized graft for the recipient with the requirement of a sufficient residual liver 
mass for the donor. Grafts over 40% of the standard liver volume are necessary in the setting 
of ALF, and outcomes are better with a graft-to-recipient weight ratio greater than 0.8, with 
1.0 being ideal (Kawasaki et al., 1998Kiuchi et al., 1999). A graft of <40% of standard liver 
weight is at risk for the development of small-for-size syndrome – portal hypertension 
following reperfusion leading to sinusoidal damage and graft injury (Man et al., 2003). In 
the absence of small-for-size syndrome following OLT, the graft and donor livers regenerate 
to full size in a matter of 4 weeks (Marcos et al., 2000). Despite these risks, right lobe LDLT 
improves survival in patients with ALF, with overall 1-year survival rates of between 60-
90%, averaging about 75% (Campsen et al., 2008; Ichida et al., 2000; S Lee et al., 2007; Miwa 
et al., 1999; Uemoto et al., 2000). For children undergoing LDLT, the 1-year survival was 67-
89% and death on the waiting list was decreased to 9% (Casas et al., 1999; Emre et al., 1999). 
In the SPLIT experience of pediatric transplantation, 57% of the recipients with ALF 
received partial grafts, without a difference in outcome compared to recipients of whole 
grafts (Baliga et al., 2004).  
Unique ethical issues exist in the setting of LDLT. Given the urgent need for an organ in this 
setting, the donor evaluation must be expedited. The time required for thorough donor 
medical and psychosocial evaluation may be truncated in the setting of rapid clinical 
deterioration of the intended recipient (Abouna, 2001). This carries the risk of an incomplete 
evaluation and the possibility of donor coercion. The 1997 Council of European 
Recommendations argued against the use of LDLT for ALF due to the theoretical risk of 
coercion, with the assumption that patients were undergoing transplantation without 
significant waiting times (Committee of Ministers, 1997). In regions where cadaveric organs 
are not as readily available, the risk of the recipient’s death while waiting for a cadaveric 
organ must be weighed against the risk to the living donor, including a 0.2% mortality 
(Ghobrial et al., 2008; Yasutomi et al., 2000). Protocols will likely need to be established to 
address these concerns (Carlisle et al., 2011; Reding, 2005).  
It has been suggested that instead of comparing the donor risks to the recipient benefits, one 
should compare the donor risks to the donor benefits. Some individuals may feel rewarded 
by being a donor (such as parent to child donation) (Spital, 2005). Mathematical modeling 
suggests the sickest patients or those with highest risk of death while on the waiting list 
would receive more benefit from living donation than those who are less sick (Durand et al., 
2006). Donors surveyed in the year following donation (two thirds responded), appeared to 
be doing well from a psychosocial perspective, but their well-being was linked to recipient 
outcomes (Kim-Schluger et al., 2002). A prospective German study evaluated the 
psychological impact on potential donors during evaluation for urgent indications for 
LDLT. They found that there was more mental stress compared to the general population, 
explained by the recipient’s severity of illness. Donors had more postoperative pain, 
particularly somatoform pain, and decreased vitality. Three months after LDLT, donor 
mental quality of life, depression, and anxiety scores were again normal, although they were 
somewhat linked to recipient outcomes (Erim et al., 2007). The US Adult-to-Adult Living 
Donor Liver Transplantation Cohort Study (A2ALL) group reported that 4.1% of all donors 
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(392) had experienced one or more psychiatric complication. Three had severe psychiatric 
complications, including suicide, accidental drug overdose, and suicide attempt, despite the 
well-being of the recipients. Although there was no clear explanation why these donors, 
despite detailed screening, would be at increased risk for psychiatric problems, they 
suggested that donors need careful preoperative assessments and perhaps prolonged post-
operative monitoring (Trotter et al., 2007).  
3.2.2 ABO-incompatible grafts 
Although ABO-identical grafts are preferred, ABO-compatible grafts (e.g., O graft; A 
recipient) have comparable 1-year patient survival following OLT and 49-54% 1-year graft 
survival (Bismuth et al., 1996a). However, ABO-incompatible grafts (e.g., A graft, B 
recipient) have less favorable outcomes and experience diminished 1-year graft survival 
rates of about 30% (Bismuth et al., 1996a). Patient survival was not affected by ABO 
compatibility for patients who had ALF, but the grafts suffered a greater incidence of 
hyperacute rejection (20%), vascular thrombosis, and/or biliary injury (56%). A Canadian 
group reported overall 5-year graft survival rates of 54–60% and 5-year patient survival 
rates of 61–77%, although the number of study subjects was small (Toso et al., 2007). The 
Birmingham group published their experience in liver transplantation for 29 children of < 5 
kg weight, five of whom underwent for ABO-incompatible grafts. They found no difference 
in transplant outcome or survival between ABO- incompatible vs. ABO-compatible graft 
(Gelas et al., 2011). A recent meta-analysis found that ABO-incompatible grafts have 
excellent outcome in children but not in adult liver transplantation (Wu et al., 2011). At 
present, up to 60% survival of the graft is generally seen in ABO-incompatible transplants, 
likely related to intensive management (use of quadruple immunosuppression, 
postoperative plasmapheresis, splenectomy, methylprednisolone, or prostaglandin E1) 
(Egawa et al., 2004; Farges et al., 1995; Hanto et al., 2003; Sugawara & Makuuchi, 2006). 
Overall, controversy remains as to whether ABO-compatible and ABO-identical OLT leads 
to equivalent post-transplant outcomes. Some studies have reported no statistical difference 
in graft survival, while others have demonstrated that patient survival is less in ABO-
compatible recipients compared to ABO-identical recipients. ABO-identical OLT is still 
preferred (Aladag et al., 2006; Bjoro et al., 2003; Koukoutsis et al., 2007); Smith et al., 2000).  
3.2.3 Auxiliary transplantation 
Auxiliary transplantation leaves the recipient’s liver in place and utilizes a partial left or 
right lobe from the donor which acts as temporary support for the recipient’s injured liver. 
Ideally, once the native liver recovers, immunosuppression may be withdrawn and the graft 
is either surgically removed or is allowed to atrophy naturally (Bismuth et al., 1996b; 
Chenard-Neu et al., 1995; Chenard-Neu et al., 1996). The partial graft is placed below the 
native liver (heterotopic auxiliary transplantation) or replaces a resected right or left native 
lobe (auxiliary partial liver transplantation.) While easier to perform, implantation of the 
heterotopic graft onto the infrahepatic vena cava may induce venous outflow obstruction, 
resulting in slower hepatocyte regeneration, presumably due to cytokine release from 
residual necrotic liver tissue. There is also an increased incidence of primary graft non-
function and portal vein thrombosis with heterotopic auxiliary transplantation compared to 
auxiliary partial or whole graft OLT (Van Hoek et al., 1999). Despite a similar patient 
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survival rate compared to conventional OLT, unique postoperative complications may 
develop following auxiliary transplantation, including biliary and neurologic problems 
(Azoulay et al., 2001). Portal blood flow is partially diverted from the native liver to the 
auxiliary graft, therefore, regeneration of the native liver and graft function may be 
impaired. Moreover, due to the smaller mass of the transplanted liver, cerebral edema and 
neurologic dysfunction may continue to progress (Bismuth et al., 1996b). In addition, 
leaving the necrotic graft in situ following immunosuppression withdrawal may lead to the 
development of multi-system organ failure, or over time, cirrhosis may develop in the 
native liver (Chenard-Neu et al., 1996; Pereira et al., 1997). 
The best outcomes with auxiliary transplantation are in young patients with hyperacute 
presentations due to a viral or autoimmune disorder, but this group also has the greatest 
chance of spontaneous recovery (Chenard-Neu et al., 1995; Chenard-Neu et al., 1996; 
Brandsaeter et al., 2002). Overall patient survival rate for auxiliary transplantation is 
reported to be between 60% and 65% and up to 85% of these survivors were able to 
discontinue immunosuppressive therapy by one year following transplantation (Bismuth et 
al., 1996b; Boudjema et al., 2002; Chenard-Neu et al., 1995; Van Hoek et al., 1999). However, 
those who had auxiliary partial transplantation have the greater 1-year survival rate, 
whereas those who underwent heterotopic transplantation had a diminished 1-year survival 
rate of only 33% (Van Hoek et al., 1999). Fifteen percent of the patients who underwent 
auxiliary transplantation had to undergo retransplantation for a variety of reasons. More 
recently, Faraj et al. looked at the long term outcome of 20 children who underwent 
auxiliary liver transplantation in the UK, the 1 and 10 year survival in this group of children 
was 85% (Faraj et al., 2010).  
4. Transplant outcomes 
Unfortunately, medical contraindications may develop quickly over the course of illness, 
thereby preventing OLT. This was demonstrated in patients with APAP-induced ALF who 
fulfilled KCH criteria. Thirty percent were not listed due to the rapid development of pre-
operative contraindications to surgery and 35% of those who were listed were eventually 
delisted or not transplanted because of rapid clinical deterioration. The majority (90%) who 
met transplantation criteria but did not undergo OLT died (Bernal et al., 1998). In the largest 
US study, 29% of ALF patients underwent OLT but 25% of those listed (10% of the entire 
group) died prior to receiving an organ (Ostapowicz et al., 2002). In general, about 15-30% of 
patients die before OLT can be performed, usually due to brain death but other causes 
include sepsis, hemodynamic instability, multiple organ failure, and gastrointestinal 
bleeding (Bismuth et al., 1995; Castells et al., 1993).  
4.1 Survival with transplantation 
There are unique postoperative issues that afflict ALF patients. Despite OLT, elevated ICP 
and cerebral edema can persist for up to a day or more. In ALF patients who die post-OLT, 
as many as 13% succumbed to brain death (Barshes et al., 2006). Protective strategies, such 
as continued ICP monitoring, may be helpful through this period of risk. Although renal 
function often improves dramatically, patients may require renal replacement therapy for 
many weeks post-OLT, particularly in the setting of APAP-ALF. Immunosuppressive 
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strategies that attempt to minimize nephrotoxic agents, such as calcineurin inhibitors, in this 
critical recovery period may be necessary. Nearly one third of post-OLT deaths in this 
setting are from bacterial or fungal infections (Barshes et al., 2006). The majority of these 
deaths occur within the first 2–3 months following the transplantation, usually due to 
neurologic complications or sepsis (Bismuth et al., 1995; DeVictor et al., 1992; Hoofnagle et 
al., 1995; W Lee, 2003; O'Grady et al., 1988; Russo et al., 2004; Wigg et al., 2005). In the largest 
Canadian study (60 patients transplanted between 1994-2007); the wait-list mortality rate 
was 6% with mean waiting time of 2.7 days. The perioperative mortality rate was 15%, and 
complications included neurological problems (13%), biliary problems (10%), and hepatic 
artery thrombosis (5%) (Chan et al., 2009). The Canadian data suggested that cerebral edema 
and extended criteria donor graft are associated with worse outcome. 
The severity of multi-organ failure at the time of OLT is a good predictor of post-
transplant survival (Devlin et al., 1995). Decreased renal function is also associated with 
worse spontaneous survival in non-APAP induced liver injury (Moore et al., 1991). In a 
multivariate analysis of UNOS data (1988-2003), four risk factors predicting post 
transplant survival were identified: history of life support, recipient age >50 years, 
recipient body mass index ≥30 kg/m2, and serum creatinine >2 mg/dL. If an individual 
had all of these risk factors, the 5-year post transplant survival was only 44-47%. Whereas, 
if none of these features were present, the 5-year post transplant survival was 82-83% 
(Barshes et al., 2006). The quality of the graft also impacts post-transplant outcome 
(Bismuth et al., 1995). Graft steatosis, reduced graft size, and ABO-incompatible grafts 
have all been shown in multivariate analyses to lead to decreased patient and graft 
survival (Bernal et al., 1998; Bismuth et al., 1995). On multivariate analysis of data from 
the United Kingdom, the strongest predictor of early mortality in seronegative ALF was 
higher donor body mass index (BMI), which may be a marker for donor graft steatosis 
(Wigg et al., 2005). This group found an odds ratio (OR) of 1.2 for every unit increase in 
donor BMI relative to a normal donor (BMI 25 kg/m2). For example, the OR for early 
death following OLT with a liver from an obese donor (BMI 35 kg/m2) is 1.2 to the power 
of 10 or 1.210 which is an OR of 6.2. The next most predictive variables were recipient age 
>50 years (OR 4.2) and non-Caucasian ethnicity (OR 4.9) Additional factors which have 
been reported to influence survival in ALF include recipient age >60 years, donor age >60 
years, and mechanical ventilation at the time of transplant (O'Mahony et al., 2007; Mas et 
al., 2010). Unfortunately, graft quality needs to be weighed against the time factor, since 
patients may deteriorate while waiting for optimal grafts, sometimes to the point when 
they are no longer feasible candidates. Suboptimal grafts may fail; however, leading to the 
need for retransplantation. 
Some advocate the use of venovenous bypass during the operation, but this is not uniformly 
practiced. Bypass is thought to minimize changes in cerebral perfusion pressure during the 
clamping of the inferior vena cava and portal vein as well as during reperfusion (Bismuth et 
al., 1996a; Jalan et al., 2003). Hepatectomy of the native liver with temporary portocaval 
anastamosis in certain patients may achieve temporary hemodynamic stabilization, with the 
expectation that a suitable graft will be available within the next 24-28 hours (Ejlersen et al., 
1994; Ringe et al., 1993).  
In infants with ALF transplanted between 1986 and 2000, only 24% had spontaneous 
recovery. Nearly half (47%) succumbed to sepsis or multiorgan failure, and 29% underwent 
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OLT, of which half were still alive at a mean follow-up of 5 years. The authors concluded 
that infants had worse prognosis with ALF, since the etiology was more commonly an 
inborn error of metabolism. Extrahepatic disease sometimes excluded OLT as a means of 
treatment (Durand et al., 2001). The Studies of Pediatric Liver Transplantation (SPLIT) 
Research Group found that 13% of all primary transplants performed between 1995 and 
2002 in children were done for ALF and that the majority of these cases were from unknown 
(indeterminate) causes (89%). The 3-month spontaneous survival was markedly diminished 
for children with ALF compared to those without (59% vs. 96%) and 6-month post-
transplant survival was lower (76% vs. 91%, respectively). The majority of children with 
ALF (80%) die from brainstem herniation. On multivariate evaluation, risk factors for post-
transplant mortality included grade 4 HE, age less than 1 year, and use of pre-transplant 
dialysis (Baliga et al., 2004).  
Over the past thirty years, however, with advances in the field of liver transplantation and 
critical care management, the US 1-year survival rates following OLT for ALF have 
improved to 60-80% and 1-year post-transplant graft survival rates have improved from 
63% to 75% (Bismuth et al., 1995; DeVictor et al., 1992; Hoofnagle et al., 1995; W Lee, 2003; 
O'Grady et al., 1988; Wigg et al., 2005). In Spain, Portugal, Belgium, and Italy, where the 
majority of ALF cases are induced by hepatitis B infection or cryptogenic causes, 1-year 
post-transplant survival is 61-79% (Areia et al., 2007; Detry et al., 2007; Escorsell et al., 2007; 
Montalti et al., 2005). These 1-year survival rates are less than the 1-year survival seen in 
patients who have been transplanted for chronic liver failure (80–90%) (Farmer et al., 2003; 
Freeman et al., 2008). However, by 1–4 years following transplantation this trend has 
reversed, and ALF patients have a better survival than those transplanted for chronic liver 
disease. Chan et al. reported the Canadian experience with 5- and 10-year patient survival 
rates of 76% and 69%, respectively, and graft survival rates of 65% and 59% (Chan et al., 
2009). Poorer outcomes are seen in centers performing less than 25 liver transplants per year 
and less than 20 split-liver grafts per year for those doing living donor liver transplantation 
(Adam et al., 2000).  
4.2 Retransplantation 
Retransplantation occurs more frequently following emergent OLT (13%) compared to 
elective OLT (7%). The cause of graft failure is usually secondary to acute cellular rejection, 
primary graft nonfunction, or intrahepatic biliary strictures, all of which may be related to 
the quality of graft used or the use of an ABO incompatible graft (Adam et al., 1991; Farges 
et al., 1995; Gugenheim et al., 1990).  
5. Quality of life 
Overall, the quality of life and long-term survival among ALF transplant survivors is good, 
but some differences have been identified. When ALF patients were compared to a matched 
control group who had undergone OLT for chronic liver disease, both groups complained of 
memory difficulties but more ALF patients complained of concentration difficulties and as a 
group scored lower on neuropsychological tests (Jackson et al., 2002). The King’s College 
group initially sent out questionnaires to small sample of ALF and chronic liver disease OLT 
recipients about 2-3 years following surgery. The ALF patients tended to be younger (35 vs. 
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59 years), so age may have influenced results. More ALF patients were employed or were in 
full-time education (50 vs. 26.5%). The mental health scores were slightly lower for those 
who had ALF (68 vs. 79; p=0.022), which was attributed to the fact that the ALF recipients 
did not undergo typical preoperative education and psychological support prior to OLT. 
There was no significant difference in parasuicide quality of life scores between the two 
groups (Sargent et al., 2006).  
ALF patients scored slightly lower in the physical function and role emotion areas 
compared to normal values, but the values were similar to those who were transplanted for 
chronic liver disease (Sargent et al., 2006). When more carefully interviewed, six ALF 
recipients described significant physical inactivity and fatigue for the first 3-6 months 
following OLT due to weight loss and loss of muscle tone. They also noted a health 
transition lasting between 3-6 months, during which time dependence on others was 
present. Pretransplant lifestyles were changed in order to regain independence. Support 
groups or role models were deemed extremely helpful in coping with the ordeal. The 
majority felt that they had been given a “second chance at life” and were willing to 
reciprocate support to other going through the same process (Sargent et al., 2007).  
Following spontaneous recovery, ALF patients with psychiatric illness who had taken a 
deliberate APAP overdose are at risk of repeated overdoses. Risk of repeated overdose 
appears to be less common; however, if the patient was transplanted, perhaps due to the 
intensity of postoperative care. In two series from the United Kingdom, APAP-ALF patients 
who underwent OLT showed similar long-term survival (median 5 years and 9 years) 
compared with patients transplanted for chronic liver disease (Cooper et al., 2009; Karvellas 
et al., 2010). Less than 5% of those transplanted for APAP overdose reattempted overdose. 
There was worse 30-day mortality for the APAP-ALF patients, and a greater probability of 
post-OLT medical nonadherence and adverse events in those who had taken APAP for 
deliberate self-harm compared with both non-APAP-ALF patients and chronic liver disease 
patients (Cooper et al., 2009).  
6. Future directions 
Hepatocyte transplantation has been studied predominantly in patients with chronic 
metabolic disorders. There is evidence, however, that partial liver engraftment is possible 
and there may be improvement in neurological status, as noted in small groups of patients 
with ALF who have undergone hepatocyte transplantation (Bilir et al., 2000; Habibullah et 
al., 1994; Strom et al., 1997). Xenotransplantation is an intriguing concept and porcine livers 
have been used for ex vivo perfusion but in vivo use has not yet proven effective due to 
problems with transspecies rejection. Bioartificial livers and extracorporeal liver assist 
devices (ELAD) have been used to bridge patients to transplantation and have 
demonstrated improved neurologic outcomes. There are two cell-based devices. One uses 
porcine hepatocytes and did not show survival advantage in one large multicenter study 
and another uses hepatoblastoma cells which was noted to decrease severity of 
encephalopathy without change in survival in one study (Demetriou et al., 2004; Ellis et al., 
1996). Non-biological systems also exist such as albumin dialysis (MARS) and 
plasmapheresis, and no survival advantage was found on meta-analysis (Khuroo et al., 
2004).  
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7. Conclusion 
Many advances have occurred that have significantly improved outcomes following 
transplantation for ALF. Prognostic models are helpful, but they are not entirely predictive 
of which individuals need OLT and which will survive without OLT. In the setting of organ 
shortage, alternatives to conventional OLT are being increasingly used, including living 
donor split grafts, ABO incompatible grafts, and auxiliary grafts, with variable outcomes. 
The risks and benefits to both the donor and the recipient must be considered. Long term 
outcomes and quality of life for both donors and recipients are good but prolonged 
monitoring may be helpful to identify those in distress. Newer technologies are being 
developed and enhanced to improve short term and long term survival after acute liver 
injury. 
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